A RANDOMIZED PHASE II STUDY OF BEVACIZUMAB (NSC# 704865) AND GEMCITABINE IN COMB

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目的：观察吉西他滨、贝伐单抗联合西妥昔单抗或吉西他滨、贝伐单抗联合OSI-774治疗晚期胰腺癌的客观有效率、毒副反应和无进展生存率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine objective response rate, toxicity and progression-free survival rate of advanced pancreatic cancer patients treated with the combination of Gemcitabine, Bevacizumab and Cetuximab or Gemcitabine, Bevacizumab and OSI-774.